A physiologically based pharmacokinetic model of mitoxantrone in mice and scale-up to humans: A semi-mechanistic model incorporating DNA and protein binding

AAPS Journal

Volumn 14, Issue 2, 2012, Pages 352-364

  An, Guohua ^a,b   Morris, Marilyn E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

DNA binding; Human scale up; Mitoxantrone; Physiologically based pharmacokinetic model

Indexed keywords

MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG DNA BINDING; DRUG HALF LIFE; DRUG HEART LEVEL; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG LUNG LEVEL; DRUG PROTEIN BINDING; DRUG SPLEEN LEVEL; DRUG TISSUE LEVEL; MACROMOLECULE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHARMACOKINETICS; PREDICTION; SIMULATION;

ANIMALS; DNA; HUMANS; MALE; MICE; MITOXANTRONE; MODELS, BIOLOGICAL; PROTEIN BINDING; TISSUE DISTRIBUTION;

EID: 84860756547     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-012-9344-7     Document Type: Article

References (41)

1. Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev. 1983;10:103-15. (Pubitemid 13001898)
2. Batra VK, Morrison JA, Woodward DL, Siverd NS, Yacobi A. Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev. 1986;17:311-29. (Pubitemid 17044696)
3. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev. 1983;10(Suppl B):3-11. (Pubitemid 14150764)
4. Young CW, Raymond V. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep. 1986;70:51-63. (Pubitemid 16140369)
5. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18:379-96. (Pubitemid 38621687)
6. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. Pharmacoki-netics and metabolism of mitoxantrone. A review. Clin Pharmacoki-net. 1990;18:365-80.
7. De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza-and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol. 1995;48:30-8.
8. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis. 1993;14:2341-51. (Pubitemid 23335192)
9. Foye WO, Vajragupta O, Sengupta SK. DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl) anthraquinones and bis(methylthio)vinylquinolinium iodides. J Pharm Sci. 1982;71:253-7. (Pubitemid 12112858)
10. Lu K, Savaraj N, Loo TL. Pharmacological disposition of 1, 4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9, 10-anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol. 1984;13:63-6. (Pubitemid 14120909)
11. Reszka R, Beck P, Fichtner I, Hentschel M, Richter J, Kreuter J. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice. J Pharmacol Exp Ther. 1997;280:232-7. (Pubitemid 27171407)
12. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs. 1985;3:109-16. (Pubitemid 15005811)
13. Richard B, Fabre G, Fabre I, Cano JP. Excretion and metabolism of mitoxantrone in rabbits. Cancer Res. 1989;49:833-7. (Pubitemid 19064331)
14. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in cancer patients. Cancer Res. 1985;45:1879-84. (Pubitemid 15079154)
15. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105-27. (Pubitemid 351560534)
16. Gerlowskiand LE, Jain RK. Physiologically based pharmacoki-netic modeling: principles and applications. J Pharm Sci. 1983; 72:1103-27. (Pubitemid 13013622)
17. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 2002;91:1488-501. (Pubitemid 34633964)
18. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13:2768-76. (Pubitemid 46788046)
19. Zaharko DS, Dedrick RL, Bischoff KB, Longstreth JA, Oliverio VT. Methotrexate tissue distribution: prediction by a mathematical model. J Natl Cancer Inst. 1971;46:775-84.
20. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol. 2002;50:373-82. (Pubitemid 35440526)
21. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Meth-otrexate pharmacokinetics. J Pharm Sci. 1971;60:1128-33.
22. Farris FF, Dedrick RL, King FG. Cisplatin pharmacokinetics: applications of a physiological model. Toxicol Lett. 1988;43:117-37.
23. Shah DK, Balthasar JP. Physiologically based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn. 2011;38:121-42.
24. An G, Morris ME. HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study. J Pharm Biomed Anal. 2010;51:750-3.
25. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-5. (Pubitemid 23211439)
26. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta. 1980; 597:1-14. (Pubitemid 10120606)
27. Courtade S, Marinetti GV, Stotz E. The structure and abundance of rat tissue cardiolipins. Biochim Biophys Acta. 1967;137:121-34.
28. Kawai R, Mathew D, Tanaka C, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther. 1998;287:457-68. (Pubitemid 29133641)
29. Terasaki T, Iga T, Sugiyama Y, Hanano M. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J Pharm Sci. 1984;73:1359-63. (Pubitemid 14021881)
30. Terasaki T, Iga T, Sugiyama Y, Hanano M. Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant. J Pharm Pharmacol. 1982;34:597-600. (Pubitemid 12018063)
31. Peng YM, Ormberg D, Alberts DS, Davis TP. Improved highperformance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. J Chromatogr. 1982;233:235-47. (Pubitemid 13151667)
32. Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA. A clinical and pharmacokinetic study of mitoxantrone in acute nonlym-phocytic leukemia. J Clin Oncol. 1987;5:391-7. (Pubitemid 17045461)
33. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in patients. Cancer Treat Rev. 1983;10(Suppl B):23-7. (Pubitemid 14150766)
34. Lown JW, Hanstock CC. High field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]. J Biomol Struct Dyn. 1985;2:1097-106. (Pubitemid 15030013)
35. Kapuscinski J, Darzynkiewicz Z. Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxan-trone (Novatrone) and their ability to condense nucleic acids. Proc Natl Acad Sci U S A. 1986;83:6302-6. (Pubitemid 17174724)
36. Rentsch KM, Schwendener RA, Pestalozzi BC, Sauter C, Wunderli-Allenspach H, Hanseler E. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Eur J Clin Pharmacol. 1998;54:83-9. (Pubitemid 28189405)
37. Rentsch KM, Horber DH, Schwendener RA, Wunderli-Allenspach H, Hanseler E. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer. 1997;75:986-92. (Pubitemid 27122616)
38. Wang YF, Ahmad A, Abu-Qare AW, Dudkowski C, Ayoub JE, Zhang A, Ahmad I. Rapid determination of liposomal and non-liposomal mitoxantrone in mouse plasma. Preclinica. 2004;2:279-86.
39. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005;7:E118-33. (Pubitemid 41554295)
40. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004;65:1208-16. (Pubitemid 38543491)
41. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry. 2002;48:59-65. (Pubitemid 34591916)